Business Standard

Friday, January 10, 2025 | 02:01 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Jubilant signs long-term supply contracts for radiopharmaceuticals in US

The US accounts for approximately 70% of the radiopharmaceuticals business' sales

Jubilant DraxImage facility
Premium

Jubilant DraxImage facility

Rakesh Rao Mumbai
Jubilant DraxImage Inc (JDI), the Montreal (Canada) based wholly-owned subsidiary of the Noida-based Jubilant Pharma, has signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans. JDI will supply these products over a period of 39 months effective from January 2017.

Jubilant DraxImage is a nuclear medicine company that develops, manufactures and commercialises radiopharmaceuticals used for the diagnosis, treatment and monitoring of disease.

“We are delighted to announce signing of long term contracts by our Jubilant Draximage business where we are the leader in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in